Alida Biosciences

Executive Summary

Alida Biosciences is a San Diego-based private biotechnology company founded in 2020, pioneering tools for epitranscriptome analysis. Its flagship EpiPlex™ platform leverages proximity barcoding and sequencing to simultaneously detect multiple RNA modifications, offering unprecedented insights into gene regulation. This technology addresses a critical gap in understanding how chemical modifications on RNA influence disease mechanisms, with potential applications in cancer, neurodegenerative disorders, and rare genetic diseases. By enabling comprehensive mapping of the epitranscriptome, Alida empowers researchers to discover novel biomarkers and therapeutic targets. The company is well-positioned in the rapidly growing epigenetics and epitranscriptomics market, projected to expand as RNA-based therapeutics gain traction. While still in early stages, Alida's proprietary approach differentiates it from competitors relying on single-modification detection. Key challenges include validation in clinical samples, scaling manufacturing, and securing commercial partnerships. The company's progress will depend on demonstrating platform reproducibility and utility in peer-reviewed studies.

Upcoming Catalysts (preview)

• Q4 2026Series A Funding Announcement70% success
• Q2 2027First Major Research Collaboration or Licensing Deal50% success
• Q3 2026Publication of Key Proof-of-Concept Study in Peer-Reviewed Journal80% success